Leishmaniasis, Cutaneous: Clinical Trials

11 trials for Leishmaniasis, Cutaneous, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 active not recruiting, 1 not yet recruiting, 1 withdrawn. 11 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 8, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 24Completed 3, Withdrawn 1

Follow Leishmaniasis, Cutaneous: new trials by email Literature Review of Leishmaniasis, Cutaneous trials Research Report on Leishmaniasis, Cutaneous

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
MILTEFOSINE gel - Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Phase 1Not yet recruitingUniversidad Industrial de Santander152026-01-012025-09-08
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
Arnica Tincture - Leishmaniasis, Cutaneous
Phase 1Active not recruitingUniversidad de Antioquia162023-05-032025-02-10
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Experimental topical (Curaleish Topical) - Leishmaniasis, Cutaneous
Phase 1 / Phase 2WithdrawnUniversidad de Antioquia2021-01-012022-06-03
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
DNDI-0690, Placebo of DNDI-0690 - Visceral Leishmaniasis, Cutaneous Leishmaniases
Phase 1CompletedDrugs for Neglected Diseases642019-04-042022-12-20
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
Liposomal amphotericin B (AmBisome®) - Cutaneous Leishmaniasis, American
Phase 1 / Phase 2CompletedHospital Universitário Professor Edgard Santos282019-03-012024-06-07
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
Sm29 Protein, Schistosoma Mansoni, Pentavalent antimony (Sbv) - Cutaneous Leishmaniasis, American
Phase 1 / Phase 2CompletedHospital Universitário Professor Edgard Santos202019-01-172023-08-21
Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
Topical Amphotericin B at 3% - Cutaneous Leishmaniasis
Phase 1 / Phase 2CompletedDrugs for Neglected Diseases802014-02-012016-07-26
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
Leish-111f + MPL-SE vaccine - Cutaneous Leishmaniasis
Phase 1CompletedAccess to Advanced Health Institute (AAHI)122005-08-012006-05-05
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
Leish-111f + MPL-SE vaccine - Leishmaniasis, Cutaneous
Phase 1CompletedAccess to Advanced Health Institute (AAHI)452004-10-012007-02-15
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
Leish-111f + MPL-SE vaccine - Leishmaniasis, Mucocutaneous
Phase 1CompletedAccess to Advanced Health Institute (AAHI)482004-07-012007-02-15
Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants
Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants - Cutaneous Leishmaniasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)501999-04-012008-03-04

Narrower conditions

Leishmaniasis (5)  ·  Leishmaniasis, Mucocutaneous (4)  ·  Leishmaniasis, Visceral (1)  ·  Parasitic Diseases (1)

Broader conditions

Euglenozoa Infections (11)  ·  Infections (11)  ·  Protozoan Infections (11)  ·  Skin Diseases (11)  ·  Skin Diseases, Infectious (11)  ·  Skin Diseases, Parasitic (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Vector Borne Diseases (11)  ·  Parasitic Diseases (10)  ·  Leishmaniasis (6)

Interventions

Arnicae flos extract (1)  ·  Interleukin-12 (1)  ·  Sm29 protein, Schistosoma mansoni (1)  ·  Solutions (1)  ·  liposomal amphotericin B (1)  ·  miltefosine (1)

Sponsors

Access to Advanced Health Institute (AAHI) (3)  ·  Drugs for Neglected Diseases (2)  ·  Hospital Universitário Professor Edgard Santos (2)  ·  Universidad de Antioquia (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Universidad Industrial de Santander (1)

Countries

Colombia (5)  ·  Brazil (3)  ·  Peru (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Alejandro Llanos-Cuentas, MD (1)  ·  Cristian Blanco, PhD (1)  ·  Evaldo Nascimento, MD (1)  ·  Franco M Piazza, MD, MPH (1)  ·  Franco M Piazza, MD, MPh (1)  ·  Ivan D Velez (1)  ·  Ivan D Velez, PhD (1)  ·  Ivan Dario Velez, Prof (1)  ·  Sharan Sidhu, MD (1)

Results publications

PMID 11353640, PMID 20851080, PMID 30044792, PMID 30815688, PMID 39147194, PMID 40825042

NIH funding

2018 (1)